title: Why transgenic and knockout animal models should be used (for drug efficacy studies in cancer).
authors.affiliation: Department of Cancer Biology, Glaxo Wellcome Research and Development Inc., Research Triangle Park, NC, USA. mpr18744@glaxowellcome.com
authors.forename: M P
authors.initials: MP
authors.lastname: Rosenberg
authors.forename: D
authors.initials: D
authors.lastname: Bortner
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use; D004354:Drug Screening Assays, Antitumor; D020022:Genetic Predisposition to Disease; D051379:Mice; D018345:Mice, Knockout; D008822:Mice, Transgenic; D009316:National Institutes of Health (U.S.); D009374:Neoplasms, Experimental / Q000188:drug therapy / Q000235:genetics; D013045:Species Specificity; D014481:United States
chemical_list: D000970:Antineoplastic Agents